photo
Speaker

Deborah Rathjen, PHD

EXECUTIVE CHAIR, BIOASIS TECHNOLOGIES, INC.
Guilford, Connecticut, United States
Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, is the previous CEO and MD at Bionomics. Dr. Rathjen joined Bionomics in 2000 from Peptech, as GM of BD and licensing. She was a co-inventor of Peptech’s TNF technology and leader of the company’s key TNF patents.

Dr. Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product R&D, BD, licensing and commercialization. Dr. Rathjen has been recognized internationally with numerous awards and honors.

Dr. Rathjen received her doctor of philosophy degree in immunology; Macquarie University; Sydney, Australia, and her B.Sc in immunology; Flinders University; Adelaide, Australia.
Speaking In
[Available On-Demand]
Bioasis is a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™…